دورية أكاديمية
Construction and validation of nomogram prognostic model for predicting survival in hepatoblastoma patients: a population-based study.
| العنوان: | Construction and validation of nomogram prognostic model for predicting survival in hepatoblastoma patients: a population-based study. |
|---|---|
| المؤلفون: | Wang S; Department of Pediatric Surgery, Tianjin Medical University General Hospital, Tianjin, China., Fu S; Department of Pediatric Surgery, Tianjin Medical University General Hospital, Tianjin, China., Li R; Department of Pediatric Surgery, Tianjin Medical University General Hospital, Tianjin, China., Guo Z; Department of Pediatric Surgery, Tianjin Medical University General Hospital, Tianjin, China., Wang Y; Department of Pediatric Surgery, Tianjin Medical University General Hospital, Tianjin, China., Sun W; Department of Pediatric Surgery, Tianjin Medical University General Hospital, Tianjin, China., Sun D; Department of Pediatric Surgery, Tianjin Medical University General Hospital, Tianjin, China. sdqchris2019@tmu.edu.cn. |
| المصدر: | Updates in surgery [Updates Surg] 2024 Aug; Vol. 76 (4), pp. 1223-1234. Date of Electronic Publication: 2024 May 25. |
| نوع المنشور: | Journal Article; Validation Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer-Verlag Italia Country of Publication: Italy NLM ID: 101539818 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2038-3312 (Electronic) Linking ISSN: 2038131X NLM ISO Abbreviation: Updates Surg Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Milano : Springer-Verlag Italia |
| مواضيع طبية MeSH: | Hepatoblastoma*/mortality , Hepatoblastoma*/pathology , Nomograms* , Liver Neoplasms*/mortality , Liver Neoplasms*/pathology, Humans ; Retrospective Studies ; Female ; Male ; Prognosis ; Survival Rate ; ROC Curve ; Child, Preschool ; Child ; SEER Program ; Adolescent ; Infant ; Middle Aged ; Proportional Hazards Models ; Adult |
| مستخلص: | For patients with hepatoblastoma (HB), current staging system is not accurate in predicting survival outcomes. The aim of this study was to develop two accurate survival prediction models to guide clinical decision making. A retrospective analysis of 424 HB patients was performed from 2004 to 2015 using the Surveillance, Epidemiology and End Results (SEER) database. Univariate and multivariate Cox regression analysis was used to screen for variables. The identified variables were used to build survival prediction model. The performance of the nomogram models was assessed based on the concordance index (C-index), calibration plot, and receiver operating characteristic (ROC) curve. The Cox regression analysis identified six variables affecting overall survival (OS) in HB patients, including race, tumor size, lymph node involvement, distant metastases, surgery and chemotherapy. And the Cox regression analysis identified five variables including race, lymph node involvement, distant metastases, surgery, and chemotherapy that affect cancer-specific survival (CCS) in HB patients. In the training cohort, the C-index of the nomogram in predicting the OS was 0.791 [95% confidence intervals (95% CI) 0.717-0.865], CSS was 0.805(95% CI 0.728-0.882). In the validation cohort, the C-index of the nomogram in predicting the OS was 0.712 (95% CI 0.511-0.913), the CSS was 0.751 (95% CI 0.566-0.936). In the training cohort, the area under the receiver operator characteristics curve (AUC) values of the nomogram in prediction of the 1-, 3-, and 5-year OS were 0.842 (95% CI 0.739-0.944), 0.759 (95% CI 0.670-0.849), and 0.770 (95% CI 0.686-0.852), respectively. In the validation cohort, the AUC values for prediction of the 1-, 3-, and 5-year OS were 0.920 (95% CI 0.806-1.034), 0.863 (95% CI 0.750-0.976), and 0.844 (95% CI 0.721-0.967), respectively. Two nomogram models were developed and validated in this study which provided accurate prediction of the OS and CSS in HB patients. The constructed models can be used for predicting survival outcomes and guide treatment for HB patients. (© 2024. Italian Society of Surgery (SIC).) |
| References: | Xie L, Onysko J, Morrison H (2018) Childhood cancer incidence in Canada: demographic and geographic variation of temporal trends (1992–2010). Health Promot Chronic Dis Prev Can 38:79–115. https://doi.org/10.24095/hpcdp.38.3.01. (PMID: 10.24095/hpcdp.38.3.0129537768) Allan BJ, Parikh PP, Diaz S, Perez EA, Neville HL, Sola JE (2013) Predictors of survival and incidence of hepatoblastoma in the paediatric population. HPB (Oxford) 15:741–746. https://doi.org/10.1111/hpb.12112. (PMID: 10.1111/hpb.1211223600968) Ranganathan S, Lopez-Terrada D, Alaggio R (2020) Hepatoblastoma and pediatric hepatocellular carcinoma: an update. Pediatr Dev Pathol 23:79–95. https://doi.org/10.1177/1093526619875228. (PMID: 10.1177/109352661987522831554479) Feng TC, Zai HY, Jiang W, Zhu Q, Jiang B, Yao L et al (2019) Survival and analysis of prognostic factors for hepatoblastoma: based on SEER database. Ann Transl Med 7:555. https://doi.org/10.21037/atm.2019.09.76. (PMID: 10.21037/atm.2019.09.76318075366861810) Spector LG, Birch J (2012) The epidemiology of hepatoblastoma. Pediatr Blood Cancer 59:776–779. https://doi.org/10.1002/pbc.24215. (PMID: 10.1002/pbc.2421522692949) Exelby PR, Filler RM, Grosfeld JL (1975) Liver tumors in children in the particular reference to hepatoblastoma and hepatocellular carcinoma: American Academy of Pediatrics Surgical Section Survey–1974. J Pediatr Surg 10:329–337. https://doi.org/10.1016/0022-3468(75)90095-0. (PMID: 10.1016/0022-3468(75)90095-049416) Lake CM, Tiao GM, Bondoc AJ (2019) Surgical management of locally-advanced and metastatic hepatoblastoma. Semin Pediatr Surg 28:150856. https://doi.org/10.1016/j.sempedsurg.2019.150856. (PMID: 10.1016/j.sempedsurg.2019.15085631931965) Venkatramani R, Stein JE, Sapra A, Genyk Y, Jhaveri V, Malogolowkin M et al (2015) Effect of neoadjuvant chemotherapy on resectability of stage III and IV hepatoblastoma. Br J Surg 102:108–113. https://doi.org/10.1002/bjs.9681. (PMID: 10.1002/bjs.968125349947) Venkatramani R, Furman WL, Fuchs J, Warmann SW, Malogolowkin MH (2012) Current and future management strategies for relapsed or progressive hepatoblastoma. Paediatr Drugs 14:221–232. https://doi.org/10.2165/11597740-000000000-00000. (PMID: 10.2165/11597740-000000000-0000022702740) Czauderna P, Otte JB, Aronson DC, Gauthier F, Mackinlay G, Roebuck D et al (2005) Guidelines for surgical treatment of hepatoblastoma in the modern era–recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL). Eur J Cancer 41:1031–1036. https://doi.org/10.1016/j.ejca.2005.02.004. (PMID: 10.1016/j.ejca.2005.02.00415862752) Meyers RL, Maibach R, Hiyama E, Häberle B, Krailo M, Rangaswami A et al (2017) Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children’s Hepatic tumors International Collaboration. Lancet Oncol 18:122–131. https://doi.org/10.1016/s1470-2045(16)30598-8. (PMID: 10.1016/s1470-2045(16)30598-827884679) Aronson DC, Czauderna P, Maibach R, Perilongo G, Morland B (2014) The treatment of hepatoblastoma: Its evolution and the current status as per the SIOPEL trials. J Indian Assoc Pediatr Surg 19:201–207. https://doi.org/10.4103/0971-9261.142001. (PMID: 10.4103/0971-9261.142001253368014204244) Gloeckler Ries LA, Reichman ME, Lewis DR, Hankey BF, Edwards BK (2003) Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 8:541–552. https://doi.org/10.1634/theoncologist.8-6-541. (PMID: 10.1634/theoncologist.8-6-54114657533) Collins GS, Reitsma JB, Altman DG, Moons KG (2015) Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ 350:g7594. https://doi.org/10.1136/bmj.g7594. (PMID: 10.1136/bmj.g759425569120) Kahla JA, Siegel DA, Dai S, Lupo PJ, Foster JH, Scheurer ME et al (2022) Incidence and 5-year survival of children and adolescents with hepatoblastoma in the United States. Pediatr Blood Cancer 69:e29763. https://doi.org/10.1002/pbc.29763. (PMID: 10.1002/pbc.29763355918059658228) El Asmar A, El Rassi Z (2016) Hepatoblastoma in childhood, long term survival achieved: 2 case reports and literature review. Int J Surg Case Rep 21:55–58. https://doi.org/10.1016/j.ijscr.2016.02.019. (PMID: 10.1016/j.ijscr.2016.02.019269423314802225) Brown J, Perilongo G, Shafford E, Keeling J, Pritchard J, Brock P et al (2000) Pretreatment prognostic factors for children with hepatoblastoma– results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer 36:1418–1425. https://doi.org/10.1016/s0959-8049(00)00074-5. (PMID: 10.1016/s0959-8049(00)00074-510899656) von Schweinitz D (2012) Hepatoblastoma: recent developments in research and treatment. Semin Pediatr Surg 21:21–30. https://doi.org/10.1053/j.sempedsurg.2011.10.011. (PMID: 10.1053/j.sempedsurg.2011.10.011) Perilongo G, Shafford E, Maibach R, Aronson D, Brugières L, Brock P et al (2004) Risk-adapted treatment for childhood hepatoblastoma final report of the second study of the International Society of Paediatric Oncology–SIOPEL 2. Eur J Cancer. https://doi.org/10.1016/j.ejca.2003.06.003. (PMID: 10.1016/j.ejca.2003.06.00315454253) Yoon HM, Hwang J, Kim KW, Namgoong JM, Kim DY, Koh KN et al (2019) Prognostic factors for event-free survival in pediatric patients with hepatoblastoma based on the 2017 PRETEXT and CHIC-HS systems. Cancers (Basel). https://doi.org/10.3390/cancers11091387. (PMID: 10.3390/cancers1109138731752148) Zhi T, Zhang WL, Zhang Y, Hu HM, Huang DS (2021) Clinical characteristics and prognostic factors of hepatoblastoma in 316 children aged under 3 years - a 14-year retrospective single-center study. BMC Pediatr 21:170. https://doi.org/10.1186/s12887-021-02630-2. (PMID: 10.1186/s12887-021-02630-2338494748042893) Katzenstein HM, Furman WL, Malogolowkin MH, Krailo MD, McCarville MB, Towbin AJ et al (2017) Upfront window vincristine/irinotecan treatment of high-risk hepatoblastoma: a report from the Children’s Oncology Group AHEP0731 study committee. Cancer 123:2360–2367. https://doi.org/10.1002/cncr.30591. (PMID: 10.1002/cncr.3059128211941) Faraj W, Dar F, Marangoni G, Bartlett A, Melendez HV, Hadzic D et al (2008) Liver transplantation for hepatoblastoma. Liver Transpl 14:1614–1619. https://doi.org/10.1002/lt.21586. (PMID: 10.1002/lt.2158618975296) Ke M, Zhou Y, Yang CZ, Li L, Diao M (2022) Analysis of risk factors for angiolymphatic invasion and establishment of a predictive nomogram for hepatoblastomas. J Pediatr Surg 57:430–437. https://doi.org/10.1016/j.jpedsurg.2022.02.024. (PMID: 10.1016/j.jpedsurg.2022.02.02435365339) Shi SJ, Wang DL, Hu W, Peng F, Kang Q (2018) Ex vivo liver resection and autotransplantation with cardiopulmonary bypass for hepatoblastoma in children: a case report. Pediatr Transplant 22:e13268. https://doi.org/10.1111/petr.13268. (PMID: 10.1111/petr.1326830003622) Hung GY, Lin LY, Yu TY, Lee CY, Yen HJ, Horng JL (2018) Hepatoblastoma incidence in Taiwan: a population-based study. J Chin Med Assoc 81:541–547. https://doi.org/10.1016/j.jcma.2017.11.012. (PMID: 10.1016/j.jcma.2017.11.01229459224) Ke M, Zhou Y, Chang-Zhen Y, Li L, Diao M (2022) A nomogram model to predict prognosis of patients with hepatoblastoma. Pediatr Blood Cancer. https://doi.org/10.1002/pbc.29932. (PMID: 10.1002/pbc.2993236031721) |
| معلومات مُعتمدة: | 81770537 National Natural Science Foundation of China; 82070554 National Natural Science Foundation of China; 21ZXGWSY00080 Major Scientific and Technological Special Project for Public Health in Tianjin; 22ZYYLCCG06 Tianjin Medical University General Hospital Clincal Research Program |
| فهرسة مساهمة: | Keywords: Cancer-specific survival; Hepatoblastoma; Nomogram; Overall survival; Prognosis; SEER |
| تواريخ الأحداث: | Date Created: 20240525 Date Completed: 20240822 Latest Revision: 20240822 |
| رمز التحديث: | 20240823 |
| DOI: | 10.1007/s13304-024-01814-6 |
| PMID: | 38795309 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 2038-3312 |
|---|---|
| DOI: | 10.1007/s13304-024-01814-6 |